类风湿关节炎患者报告结局测量在易受不公平影响人群中的验证研究:基于OMERACT测量性能公平性总结表的系统综述与分析
该系统综述检索MEDLINE和EMBASE,从19786条题录中纳入14项独特验证研究,评估疼痛、DAS28-ESR或DAS28-CRP、ACR20、患者整体评估、EQ5D和PROMIS®等患者报告结局测量在种族、年龄、性别、教育水平、残疾、识字、就业状况、社会支持水平和社会经济地位等易受不公平影响人群中的可行性、结构效度和判别效度。按文化和语言分组的验证研究均被评为测量性能指标良好,其他易受不公平影响人群的测量性能评估有限。
要点
- 按文化和语言分组的验证研究均被评为测量性能指标良好
- 其他易受不公平影响人群的测量性能指标评估有限
- 风湿病研究中已接受结局测量在患者代表性方面存在重要空白
核心结论
- 本研究凸显了风湿病研究中已接受结局测量在患者代表性方面存在重要空白。
- 为新研究和临床实践开发的新结局测量应确保并报告易受不公平影响人群在可行性、结构效度和判别能力指标测试中的代表性。
研究设计与样本
- 系统综述,检索MEDLINE和EMBASE,筛选19786条题录和摘要,纳入14项独特验证研究。
- 纳入实验性、观察性和定性研究,报告类风湿关节炎患者报告结局测量在易受不公平影响人群中的可行性、结构效度和判别能力指标分析。
- 按OMERACT测量性能公平性总结表对证据进行评级。
主要发现
- 纳入的14项研究中,疼痛n=3、DAS28-ESR或DAS28-CRP n=2、ACR20 n=1、患者整体评估n=2、EQ5D n=4、PROMIS® n=3。
- 按种族分析10项研究、年龄6项、性别5项、教育水平2项,残疾、识字、就业状况、社会支持水平和社会经济地位各1项研究。
- 5项研究报告可行性,12项报告结构效度指标,4项报告判别效度指标。
- 所有按文化和语言分组的验证研究均被评为测量性能指标良好。
关键数值与推荐
- 按OMERACT测量性能公平性总结表评级:所有按文化和语言分组的验证研究均被评为测量性能指标良好。
- 其他易受不公平影响人群的测量性能指标评估有限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 其他易受不公平影响人群的测量性能指标评估有限。
- 风湿病研究中已接受结局测量在患者代表性方面存在重要空白。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Existing patient-reported outcome measures (PROMs) in rheumatoid arthritis (RA) may be limited in their applicability to populations that are at risk for inequities. We conducted a systematic review to identify and rate evidence in the validation studies for PROMs in populations at risk for inequity. METHODS: A systematic review of MEDLINE and EMBASE was completed. The search strategy was developed to identify measurement property studies for PROMs of interest (selected pain, disease activity, global evaluation and quality of life scales) in patients with RA. We identified experimental, observational, and qualitative studies reporting analysis of feasibility, construct validity and discriminant ability metrics for populations at risk for inequity by various factors including race, ethnicity, culture or language; employment status; sex and gender identity; education level; socioeconomic status; social support; age; health literacy and disability. These were rated based on the OMERACT Summary of Measurement Properties Equity table. RESULTS: From 19,786 titles and abstracts screened, we identified 14 unique studies reporting validation metrics for pain (n = 3), DAS28-ESR or DAS28-CRP (n = 2), ACR20 (n = 1), patient global assessment (n = 2), EQ5D (n = 4), and PROMIS® (n = 3) by race (n = 10 studies), age (n = 6 studies), sex (n = 5 studies), education level (n = 2 studies), and disability, literacy, employment status, social support level and socioeconomic status (n = 1 study each). Five studies reported on feasibility, 12 reported construct validity metrics, and 4 studies reported on discriminant validity metrics. All studies by culture or language were rated as having good measurement property metrics. There was limited assessment of measurement property metrics for other populations at risk for inequity. CONCLUSION: Our study highlights important gaps in patient representation in rheumatology research for accepted outcome measures. New outcome measures being developed for research purposes and clinical practice should ensure and report representation of patients from populations at risk for inequities in the testing of metrics of feasibility, construct validity and discriminant ability metrics.
引用
- Barnabe C, Wattiaux A, Petkovic J, et al. Validation studies of rheumatoid arthritis patient-reported outcome measures in populations at risk for inequity: A systematic review and analysis using the OMERACT summary of measurement properties equity table. Semin Arthritis Rheum. 2022. PMID: 35640489. doi:10.1016/j.semarthrit.2022.152029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。